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Catheter Ablation of Ventricular Tachycardia in Patients With
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia:
A Sequential Approach
Shibu Mathew, MD;* Ardan M. Saguner, MD;* Niklas Schenker, MD; Lukas Kaiser, MD; Pengpai Zhang, MD; Yoshiga Yashuiro, MD;
Christine Lemes, MD; Thomas Fink, MD; Tilman Maurer, MD; Francesco Santoro, MD; Peter Wohlmuth, PhD; Bruno Reißmann, MD;
Christian H. Heeger, MD; Roland Tilz, MD; Erik Wissner, MD; Andreas Rillig, MD; Andreas Metzner, MD; Karl-Heinz Kuck, MD;
Feifan Ouyang, MD
Background-—It has been suggested that endocardial and epicardial ablation of ventricular tachycardia (VT) improves outcome in
arrhythmogenic right ventricular cardiomyopathy/dysplasia. We investigated our sequential approach for VT ablation in patients
with arrhythmogenic right ventricular cardiomyopathy/dysplasia in a single center.
Methods and Results-—We included 47 patients (4416 years) with deﬁnite (81%) or borderline (19%) arrhythmogenic right
ventricular cardiomyopathy/dysplasia between 1998 and 2016. Our ablation strategy was to target the endocardial substrate.
Epicardial ablation was performed in case of acute ablation failure or lack of an endocardial substrate. Single and multiple
procedural 1- and 5-year outcome data for the ﬁrst occurrence of the study end points (sustained VT/ventricular ﬁbrillation,
heart transplant, and death after the index procedure, and sustained VT/ventricular ﬁbrillation for multiple procedures) are
reported. Eighty-one radiofrequency ablation procedures were performed (mean 1.7 per patient, range 1–4). Forty-ﬁve (56%)
ablation procedures were performed via an endocardial, 11 (13%) via an epicardial, and 25 (31%) via a combined endo- and
epicardial approach. Complete acute success was achieved in 65 (80%) procedures, and partial success in 13 (16%). After a
median follow-up of 50.8 (interquartile range, [18.6; 99.2]) months after the index procedure, 17 (36%) patients were free
from the primary end point. After multiple procedures, freedom from sustained VT/ventricular ﬁbrillation was 63% (95% CI,
52–75) at 1 year, and 45% (95% CI, 34–61) at 5 years, with 36% of patients receiving only endocardial radiofrequency
ablation. A trend (log rank P=0.058) towards an improved outcome using a combined endo-/epicardial approach was
observed after multiple procedures.
Conclusion-—Endocardial ablation can be effective in a considerable number of arrhythmogenic right ventricular cardiomyopathy/
dysplasia patients with VT, potentially obviating the need for an epicardial approach. ( J Am Heart Assoc. 2019;8:e010365. DOI:
10.1161/JAHA.118.010365.)
Key Words: arrhythmogenic right ventricular dysplasia/cardiomyopathy • catheter ablation • epicardial ablation • ventricular
tachycardia
A rrhythmogenic right ventricular cardiomyopathy/dys-plasia (ARVC/D) is an inherited cardiomyopathy leading
to ﬁbro-fatty inﬁltration, which predominantly occurs in the
right ventricular (RV) myocardium resulting in ventricu-
lar tachycardia (VT) and ﬁbrillation (VF).1,2 Implantable
cardioverter-deﬁbrillators (ICD) are the only therapeutic
measure that have been shown to improve prognosis in this
challenging disease,3,4 but frequent appropriate ICD interven-
tions can lead to a reduced quality of life.5,6 Therefore,
therapies to reduce these ICD interventions are needed.
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Pathologically, ﬁbro-fatty inﬁltration typically begins in the
subepicardial layers and progresses towards the endocardium
over time.7–9 In line with these ﬁndings, recent observational
studies have suggested that additional epicardial ablation
seems to be more effective than only endocardial ablation to
control sustained VT.10–13 This evidence is reﬂected in a
recent task force consensus document on the treatment of
ARVC/D, in which an epicardial approach is recommended in
patients who fail ≥1 attempts of endocardial VT ablation, or
even a combined endocardial/epicardial VT ablation approach
as the initial ablation strategy.14 However, procedure-
associated complications of combined endo/epicardial abla-
tion are thought to be higher as compared with a solely
endocardial approach and occur in up to 8% of patients.15–19
Furthermore, epicardial fat is predominantly located in the RV
free wall, especially along the tricuspid annulus. This region is
frequently affected by the process of ﬁbro-fatty inﬁltration in
ARVC/D, and VT often arise from this region. However, the
presence of large amounts of epicardial fat in this region can
reduce the efﬁcacy of epicardial RF lesions, and potentially
hamper coronary arteries that are located along the tricuspid
annulus.20,21 Therefore, in the present study, we investigated
the clinical outcome of ablating sustained VT using our
sequential approach in a large single-center cohort of patients
with ARVC/D.
Methods
Study Population
The study population consisted of 47 adult patients with ARVC/
D who were enrolled in our center for catheter ablation of VT
between 1998 and 2016. No patient with ARVC/D who
received catheter ablation for VT at our center was excluded
from this analysis. All patients had at least 1 symptomatic
episode of sustained monomorphic VT documented by 12-lead
ECG, Holter monitoring, or interrogation of the ICD. All patients
gave written informed consent to the ablation procedure. The
local ethical committee approved this retrospective study
(reference number PV5039). The diagnosis of ARVC/D was
fulﬁlled according to the 2010 revised Task Force criteria22 with
either deﬁnite (81%) or borderline (19%) criteria. The data that
support the ﬁndings of this study are available from the
corresponding author upon reasonable request.
Electrophysiologic Study
The procedure was performed in the fasting state with propofol
(1–4 mg/kg per hour), midazolam, and fentanyl or sufentanyl.
All antiarrhythmic drugs (AAD) (except amiodarone) were
discontinued for ≥5 half-lives before the procedure. Two 6F
diagnostic catheters were positioned in the right ventricle (RV)
and within the coronary sinus. The stimulation protocol
consisted of programmed stimulation from the RV at 2 drive
cycle lengths (CL; 510 and 440 ms) with up to 3 extra stimuli to
a minimum coupling interval of 200 ms. Burst-pacing with the
shortest CL of 250 ms was also used if induction failed with
programmed stimulation. If sustained VT was non-inducible at
baseline, intravenous isoproterenol infusion (2–10 lg/min)
was administered to induce VT. Clinical VT was deﬁned as the
same12-lead surface electrocardiogram (QRS)morphology and
similar CL, or similar CL to the documented VT in patients with
ICDs and without a 12-lead ECG documentation. Other induced
VT were considered as non-clinical VT.
Electroanatomical Mapping and Ablation
Our primary ablation strategy was to target the endocardial
substrate. Epicardial ablation was performed only in cases of
acute ablation failure or lack of an endocardial substrate
(sequential approach; if required, epicardial ablation was
performed within the same procedure such as endocardial
ablation). For clariﬁcation, endocardial approach indicates
that mapping/ablation was only performed from the
endocardium, whereas epicardial approach indicates that
mapping/ablation was only performed from the epicardium.
Combined endo-epicardial approach indicates that mapping/
ablation was performed from both, the endocardium and
Clinical Perspective
What Is New?
• In this study we used a stepwise catheter ablation approach
to treat patients with arrhythmogenic right ventricular
cardiomyopathy/dysplasia and sustained ventricular
arrhythmias.
• Adjuvant epicardial ablation was only performed in cases of
ablation failure or lack of an endocardial substrate.
What Are the Clinical Implications?
• Current consensus documents propose combined endocar-
dial and epicardial ablation during the initial procedure in
these patients.
• Although we observed a trend towards improved arrhyth-
mia-free survival with adjuvant epicardial ablation, our study
shows that endocardial ablation only can be effective in a
considerable number of patients with arrhythmogenic right
ventricular cardiomyopathy/dysplasia with sustained ven-
tricular arrhythmias, obviating the need for a more risky
epicardial approach that may cause pericardial adhesions
potentially precluding future epicardial access.
• Moreover, multiple ablation procedures are often necessary
to improve long-term arrhythmia-free survival in this
progressive and challenging disease.
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epicardium within the same procedure. Mapping was per-
formed using a 7F 3.5 mm tip (Navistar Thermocool, Biosense
Webster Inc., Diamond Bar, CA) through the femoral vein
under ﬂuoroscopic guidance. Our methods were previously
described in detail.16 In brief, 3D electroanatomic maps (EAM)
were performed during sinus rhythm (SR) and/or during VT in
case of stable and reproducible VT. Activation and voltage
maps were both used to guide the ablation strategy. Low
voltage amplitudes in bipolar electrograms were deﬁned as
<1.5 mV for endocardial maps, <1.0 mV for epicardial maps,
and <0.5 mV for delineating dense scar. Also, endocardial
unipolar voltage <5.5 mV was deﬁned as abnormal ampli-
tudes.23 In addition, sites with prolonged (>70 ms), fraction-
ated (deﬁned as >2 potentials without an isoelectric
interval)24 or late potentials were tagged on 3D maps.
Ablation was performed at the site of diastolic potentials
during VT in case of stable VT and short post pacing intervals
after entrainment of the VT or guided by pace mapping at the
substrate area with fractionated or late potentials. Frag-
mented low voltage signals or late potentials that were judged
to be crucial to maintain the induced VT circuit were targeted
for ablation. If no sustained VT was inducible, all fragmented
low voltage signals/late potentials in the region where the
documented clinical VA were suspected were eliminated.
Irrigated radiofrequency current was delivered in power-
controlled mode, power 30 to 40 W, irrigation 17 to 30 mL/
min, and temperature limit 43°C.
Epicardial access was obtained through an anteriorly
oriented subxiphoid puncture. In brief, after reaching the
pericardial space, contrast agent was injected to verify the
position of the needle in the pericardial space, and a long
J-tipped guidewire was placed via the needle in the pericardial
space. After positioning a long 8.5 Fr SL-1 sheath in the
pericardial space over the guidewire, the ablation catheter
was advanced into the pericardial space.
Coronary angiography was not performed on a routine
basis before epicardial ablation, but only in cases where the
substrate was in close proximity to the tricuspid valve and the
course of the right coronary artery. Ablation energy was
delivered applying a power of 30 to 40 W, ﬂush rate 17 to
20 mL/min and maximum temperature of 43°C. Repeat
aspiration of irrigation ﬂuid was performed depending on
hemodynamic status or after every ﬁfth radiofrequency
application within the epicardial space. We did not use
invasive hemodynamic support like extracorporeal membrane
oxygenation (ECMO) or a left ventricular assist device (LVAD
system) during the procedure.
End points
The procedural end point was non-inducibility of any sustained
VT by programmed stimulationisoproterenol at the end of
the procedure (complete success). Partial success was
deﬁned as non-inducibility of clinical VT, but remaining
inducibility of non-clinical sustained VT or fast VT (CL
<240 ms). In case of lack of VT inducibility before ablation,
the procedural end point was elimination of all fragmented
low voltage signals/late potentials in the region where the
documented clinical VT/frequent premature ventricular con-
tractions were suspected. Acute ablation failure was deﬁned if
clinical VT remained inducible. Our combined study end point
consisted of 3 components (recurrent sustained VT/VF
including any appropriate ICD intervention, namely shock or
anti-tachycardia pacing [ATP], heart transplant, or death
during follow-up, whatever came ﬁrst), indicating the occur-
rence of any of these 3 components after the ﬁrst RFA
procedure. Our secondary end point was recurrent sustained
VT/VF after multiple procedures, indicating the occurrence of
any sustained ventricular arrhythmia including ICD interven-
tions after the last RFA procedure. Arrhythmia burden was
determined in a subset of patients in whom complete ICD
interrogation information was available for detailed review and
analysis before and after the index ablation procedure.
Complications and Follow-Up
Major complications were deﬁned as transient ischemic
attack (TIA), stroke, pericardial tamponade, pneumo- or
hemothorax, or severe bleeding from the access sites or
internal bleeding resulting in hemorrhagic shock. Hematoma
at access sites not requiring surgical intervention or blood
transfusion and pericardial effusion/pericarditis were consid-
ered minor complications.
All patients were followed routinely in our outpatient clinic
or by their treating cardiologists at 3- to 6-month intervals. In
patients with implanted ICD, the interrogation reports were
reviewed by experienced cardiologists. Recurrence of VT and
appropriateness of ICD therapy were determined based on
review of the stored electrograms. In patients without ICDs, VT
recurrence was based on ECG or Holter documentation.
Baseline and follow-up data were obtained from hospital
records, treating physicians, telephone interviews with
patients and/or their family members, and a structured pre-
designed patient questionnaire at last follow-up.
Statistical Analysis
Continuous variables were summarized as meanSD or
median (interquartile range). Categorical variables were
expressed as frequencies (percentages). We examined 2
survival end points by Kaplan–Meier estimates: (1) A
combined event composed of 3 components deﬁned as the
ﬁrst occurrence of a sustained ventricular arrhythmia, heart
transplantation, or death and (2) recurrent sustained
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ventricular arrhythmias (VT/VF) after multiple procedures.
The log-rank test was used to examine the end points with
regard to endocardial alone versus combined endo-/epicar-
dial ablations. A multiple Cox proportional hazards model was
used to examine effects of sex, body mass index, ARVC 2010
diagnostic score, ICD, and ablation type on the combined
survival end point. Survival differences between the ablation
types were expressed with P values and hazard ratios (95%
CI). Sustained VT/VF burden before and after the index
ablation procedure was analyzed using a linear mixed effects
model to account for different time durations. Differences in
procedural data between ablation types were compared with
linear mixed effect models considering multiple procedures of
patients. A logistic regression model was used to compare the
amount of RF lesions in patients with and without pericardial
adhesions. A McNemar test was used to compare AAD taken
before index procedure and at last follow-up. A Mann–
Whitney-U test was used to compare VT inducibility in patients
with primary and secondary implanted ICD. All P values are 2-
sided. P<0.05 was considered statistically signiﬁcant. Statis-
tical analysis was performed using R (version 3.2.3).
Results
Patient Characteristics
Clinical characteristics are provided in Tables 1 and 2. Thirty-
eight patients (38/47, 81%) fulﬁlled a deﬁnite diagnosis of
ARVC/D, and 9 (9/47, 19%) a borderline diagnosis according
to the revised 2010 TFC. From the 6 diagnostic categories, a
structural major or minor criterion was present in 64% (30/
47), an ECG repolarization criterion in 66% (31/47), an ECG
depolarization criterion in 51% (24/47) (Epsilon waves in 17%
[8/47]), an arrhythmia criterion in 98% (46/47), and a family
criterion in 19% (9/47). Myocardial biopsy to assess for
tissue alterations was not performed in any patient. The
majority of patients were male (38/47, 81%). An ICD was
implanted in 35 (35/47, 74%) patients at the time of their
ﬁrst ablation procedure. Most patients were either on
betablockers (n=15/44, 34%) or sotalol (n=14/44, 32%).
Genetic testing was available in 11 (11/47, 23%) patients.
Eight out of those 11 patients (8/11, 73%) harbored a
desmosomal mutation (Table 1). There was one proband
carrying a heterozygous plakophilin-2 (PKP-2) and
Table 1. Clinical Characteristics of the Study Cohort (n=47)
Characteristic All Patients (n=47)
Age at index ablation, y 4416
Age at first ARVC/D diagnosis 4014
Male 38/47 (81)
Patients alive at last follow-up 43/47 (91)
rTFC criteria
Definite 38/47 (81)
Borderline 9/47 (19)
Presenting symptoms at baseline n=32 (68)
SCD (survived) 4/32 (13)
Palpitations 19/32 (59)
Syncope 6/32 (19)
Dyspnea 2/32 (6)
Chest pain 1/32 (3)
ICD at index ablation n=35 (74)
Primary prophylaxis 5/35 (14)
Secondary prophylaxis 30/35 (86)
AAD at index ablation 44 (94)
>Betablocker 15/44 (34)
>Sotalol 14/44 (32)
>Amiodaron 5/44 (12)
>Flecainid 1/44 (2)
>Betablocker+amiodaron 7/44 (16)
>Betablocker+flecainid 1/44 (2)
>Other combinations 1/44 (2)
AAD at last follow-up 42 (89)
>Betablocker 11/42 (26)
>Sotalol 9/42 (21)
>Amiodaron 4/42 (10)
>Flecainid 3/42 (7)
>Betablocker+amiodaron 10/42 (24)
>Betablocker+flecainid 4/42 (10)
>Other combinations 1/42 (2)
Mutation status n=11/47 (23)
Single desmosomal mutation 7/11 (64)
PKP-2 6/7 (86)
DSG-2 1/7 (14)
Digenic heterozygosity for desmosomal mutations 1/11 (9)
Continued
Table 1. Continued
Characteristic All Patients (n=47)
No mutation 3/11 (27)
Former endurance athlete 22* (92)
Left ventricular EF <55% at baseline 5/47 (11)
Values are meansSD and numbers (percentages). AAD indicates antiarrhythmic drugs;
ARVC/D, arrhythmogenic right ventricular cardiomyopathy/dysplasia; DSG-2,
desmoglein-2; EF, ejection fraction; ICD, implantable cardioverter-deﬁbrillator; PKP-2,
plakophilin-2; rTFC, 2010 revised ARVC/D Task Force Criteria; SCD, sudden cardiac
death.
*Data available in n=24.
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desmoplakin (DSP) mutation. Genetic testing for the 3
remaining patients did not reveal any pathogenic mutation.
Five out of 47 patients (5/47, 11%) had LV involvement
with a reduced LV function. Twenty-two out of 24 patients
(22/24, 92%), in whom data on sports activity were available,
were former endurance athletes. In the remaining patients
data on sports activity could not be retrieved.
Procedural Data and Complications
A total of 81 RFA procedures were performed during the study
period (mean 1.7 per patient, range 1–4). Forty-ﬁve (45/81,
56%) ablation procedures were performed via an endocardial
approach, 11 (11/81, 13%) via an epicardial approach, and 25
(25/81, 31%) via a combined endo- and epicardial approach.
Procedural data are provided in Table 3. The mean number of
induced VT was 2.01.0 per procedure. VT inducibility in the
subgroups of patients with a primary prophylactic ICD (n=5)
and a secondary prophylactic ICD (n=30) did not differ
signiﬁcantly. The mean number of induced VT was 2.01.19
in the primary prevention group and 1.721.08 in the
secondary prevention group.
Fourteen out of 47 patients (14/47, 30%) received a single
ablation procedure, whereas the majority (n=33/47, 70%) had
multiple procedures. Four out of 47 patients (4/47, 9%)
underwent a total of 4 ablations.
Five out of 47 patients (5/47, 11%) had LV involvement
with a reduced LV function. Ablation strategy did not differ
between those with a normal LVEF and those with reduced LV
function.
Total procedure time tended to be shorter for endocardial
procedures as compared with epicardial/combined endo-/
epicardial procedures (250 [195; 345] versus 300 [240; 360]
minutes; P=0.06). Complete acute success was achieved in
65 out of 81 procedures (65/81, 80%), and partial success in
13 (13/81, 16%) procedures. Ablation failure was docu-
mented in 2 patients (3 procedures); in 1 patient this was
because of the close proximity of the RV lead and the critical
substrate, and in the remaining patient clinical VT was still
inducible even after extensive endocardial and epicardial
ablation of the substrate.
A major complication occurred in 1 patient (1/81, 1%)
who developed pericardial tamponade during the procedure,
which was attributed to the epicardial access and was
managed without any surgical measures and without any
further sequelae. Minor complications occurred in 9 patients
in 81 procedures (9/81, 11%), which were associated with
endocardial procedures in 5 patients. Of note, 4 patients (4/
28 patients with epicardial access, 14%) developed pericar-
dial adhesions lately after epicardial access, precluding a
second epicardial access by conventional epicardial punc-
ture during follow-up. In these patients the total amount of
RF lesions (range 0–35 per procedure) was not signiﬁcantly
higher as compared with those without pericardial adhesions
(P=0.41).
Characteristic Pattern of the VT Substrate in
ARVC/D
As indicated in Table 3, the substrate for VT in the endocar-
dial and epicardial maps was most frequently localized in the
subtricuspid area (n=54/95 documented VT sites, (57%) and
n=23/48 documented VT sites, (48%), respectively) followed
by the right ventricular outﬂow tract (RVOT) (n=27/95, (28%)
and n=16/48, (33%), respectively). In those patients with
both endo- and epicardial maps, the area of epicardial bipolar
low voltage was signiﬁcantly larger as compared with the
endocardial low voltage area (75.930.8 cm2 versus 32.1
21.9 cm2; P<0.001; epicardial/endocardial low voltage ratio
2.1 for deﬁnite ARVC/D, and 1.8 for borderline ARVC/D,
respectively). No signiﬁcant differences in the location of low
voltage areas and the total area of epicardial and endocardial
low voltage were observed between both subpopulations of
deﬁnite and borderline patients (74.235.6 cm2 versus
67.24.5 cm2, and 36.033.3 cm2 versus 38.020.1 cm2,
respectively).
Table 2. Detailed Chart Listing the Diagnostic Criteria for
ARVC/D (rTFC)
Characteristic All Patients (n=47)
Structural rTFC 30/47 (64)
Major criterion 28/30 (60)
Minor criterion 2/30 (4)
Tissue alterations rTFC Not available
Major criterion 
Minor criterion 
Repolarization rTFC 31/47 (66)
Major criterion 24/31 (51)
Minor criterion 7/31 (15)
Depolarization rTFC 24/47 (51)
Major criterion 8/24 (17)
Minor criterion 16/24 (34)
Arrhythmia rTFC 46/47 (98)
Major criterion 34/46 (72)
Minor criterion 12/46 (26)
Family rTFC 9/47 (19)
Major criterion 8/9 (17)
Minor criterion 1/9 (2)
Values are numbers (percentages). ARVC/D indicates arrhythmogenic right ventricular
cardiomyopathy/dysplasia; rTFC, Task Force Criteria (revised 2010).
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All patients had an enlarged RV measured by the
endocardial 3D EAM with a volume of >100 mL/m2 (mean
247.991.9 mL).
Of note, 2 patients showed no low voltage/dense scar on
endocardial voltage maps, but the corresponding epicardial
voltage maps displayed a typical pathological substrate in the
subtricuspid region. Low voltage areas often presented as a
“C-shape pattern” in the RV extending from the RVOT free wall
to the inferior RV, which is more frequently visible on
epicardial maps as compared with endocardial maps (61.1%
versus 21.9%). This C-shape pattern was not only present in
patients with deﬁnite ARVC/D, but also in those with
borderline ARVC/D. The pathological process of ﬁbro-fatty
inﬁltration in ARVC/D typically begins in the subtricuspid
region, then extending towards the RVOT free wall, whereas
the RV apex is involved at more advanced disease stages8
(Figure 1A). Of note, the epicardial low voltage areas were
conﬂuent in all patients with deﬁnite disease having >1 RV
region involved (Figure 1B). The only patient, in whom no
conﬂuent low voltage areas between the diseased RV regions
were observed had borderline ARVC/D. Since bipolar endo-
cardial voltage maps were less sensitive to display the
pathologic process of ﬁbro-fatty inﬁltration as compared with
the epicardial voltage maps, this typical “C-shape pattern” of
disease involvement was not present in 42.9% of the
endocardial bipolar maps.
Follow-Up and Ventricular Arrhythmia Burden
The combined study end point was reached by 30 patients
(30/47, 64%). Out of these, 11 patients (11/30, 37%)
presented with an appropriate ICD intervention attributable
to VT/VF, 18 patients (18/30, 60%) with sustained VT without
an ICD intervention, and 1 patient (1/30, 3%) underwent heart
transplantation. Four patients died during follow-up after they
had previously suffered from 1 of the other components of the
primary study end point. The cause of death was decompen-
sated heart failure in 2 patients; 1 patient developed a severe
sepsis unrelated to the ablation procedure (54 days after the
ablation procedure), and 1 cause of death was not clariﬁed.
ICD interrogations before and after the index procedure
were analyzed to determine the effectiveness of catheter
Table 3. Electrophysiologic Characteristics of All Procedures
(n=81) in the Whole Study Cohort
Characteristic All Procedures (n=81)
Endocardial approach only 45 (56)
Epicardial approach only 11 (13)
Combined epi-/endocardial
approach
25 (31)
No. of VTs induced
1 30 (37)
2 16 (20)
≥3 25 (31)
Only PVCs 10 (12)
Cycle length of induced VTs,
ms
35379
Induction method
Extra stimuli 64 (79)
Isoprotenerolburst
pacing
6 (7.5)
Spontaneous 6 (7.5)
Multiple induction methods 5 (6)
VT morphology (n=78 documented morphologies)
LBBB superior axis 25 (32)
LBBB inferior axis 18 (23)
RBBB superior axis 0 (0)
RBBB inferior axis 0 (0)
Multiple morphologies 34 (44)
Indeterminate axis 1 (1)
Critical site for endocardial VT (n=95 documented VT sites)
Subtricuspid area 54 (57)
RVOT 27 (28)
Inferior RV/apex 13 (14)
LV 1 (1)
Critical site for epicardial VT (n=48 documented VT sites)
Subtricuspid area 23 (48)
RVOT 16 (33)
Inferior RV/apex 7 (15)
LV 2 (4)
Procedure time, min* 250 (195; 345) [endo]; 300 (240; 360)
[comb.]
Fluoroscopy time, min 13.5 (8; 18) [endo]; 20.0 (12; 29)
[combined]
Dose of radiation, cGy9cm2 1363 (770; 4042) [endo]; 2533 (1373;
5246) [c.]
Continued
Table 3. Continued
Characteristic All Procedures (n=81)
Acute success
Complete success 65 (80)
Partial success 13 (16)
No success 3 (4)
Values are meansSD and numbers (percentages). LBBB indicates left bundle branch
block; LV, left ventricle; PVC, premature ventricular contraction; RBBB, right bundle
branch block; RV, right ventricle; RVOT, right ventricular outﬂow tract; VT, ventricular
tachycardia.
*Deﬁned from peripheral venous access to removal of all endovascular sheaths.
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ablation at the short term. Figure 2 illustrates the number of
appropriate ICD therapies for sustained VT/VF episodes in the
year before and the time (median 37.2 [2.5; 78.8] months)
after the index procedure. The median number of VT/VF
episodes before the index ablation procedure was 23 [7; 55]
as compared with 0 [0; 1] after ablation (P<0.001).
From patients with ICD shocksATP (n=25) before the
index procedure, the majority (n=15/25, 60%) had no further
ICD intervention after the index procedure. More than half of
these patients (n=8/15, 53%) only received an endocardial
ablation. Figure 3 shows an endocardial EAM and the targeted
clinical VTs in a patient with deﬁnite ARVC/D (harboring a
digenic heterozygous PKP-2/DSP mutation), who presented
with electrical storm and multiple ICD interventions before the
index ablation procedure. During endocardial mapping, a
pathological substrate was found in the subtricuspid area and
in the RVOT. Ablation only via an endocardial approach was
performed, and has been successful with no more sustained
VT/VF episodes after a follow-up of 2 years. Patients with only
ATP before the index procedure (n=3/25) did not experience
any further ICD intervention after their index ablation.
There were 12 patients (12/47, 26%) in our cohort who did
not have an ICD. In these patients, VT ablation was performed
because of VT inducibility during the electrophysiologic study
and previously observed sustained VT during Holter monitor-
ing. All of these procedures were completely successful.
During follow-up, 6 of these patients (6/12, 50%) suffered
from sustained VT which was addressed by a second ablation
procedure. During follow-up none of them suffered from
sustained VT and none of them died from a cardiovascular
cause. Therefore, cardiovascular mortality was not increased
in this subpopulation of our patients without ICDs.
Three patients (3/35 patients with ICD, 9%), 2 of them with
a deﬁnite ARVC/D diagnosis, suffered from electrical storm
after the index procedure (2 with only endocardial ablation, 1
with combined endo-/epicardial ablation).
Out of the 9 patients with a borderline ARVC/D diagnosis,
4 patients (4/9, 44%) did not have any sustained VT/VF
recurrence during follow-up. The remaining 5 patients (5/9,
56%) received ICD shocks and were admitted for a second
ablation procedure after the index procedure. In comparison,
out of the 38 patients with a deﬁnite ARVC/D diagnosis, a
second ablation procedure because of sustained VT/VF
recurrence was performed in 25 patients (66%, P=0.60).
Long-Term Follow-Up
After a median follow-up of 50.8 [18.6; 99.2] months after the
index procedure, 17 (17/47, 36%) patients were free from the
Figure 1. Endocardial (A) and epicardial (B) electroanatomical voltage map in right anterior oblique
projection in a patient with a deﬁnite diagnosis of arrhythmogenic right ventricular cardiomyopathy/
dysplasia. The endocardial map (A) shows a low voltage area in the subtricuspid region (which is
usually the ﬁrst region, where the disease begins), whereas the epicardial map (B) shows more
extensive scarring in a typical “C-shape pattern” extending from the right ventricular outﬂow tract
free wall to the inferior right ventricle and right ventricle apex.
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combined study end point (sustained VT/VF, heart transplant,
and death). The median time from the index procedure to this
end point was 1.9 [0.2; 11.3] months. After a median follow-
up of 15.5 [0.7; 47.3] months since the last ablation
procedure, 39 (39/47, 83%) patients were free from any
sustained VT/VF. Eight (8/47, 17%) patients had recurrent
ICD interventions after the last procedure, and 3 (3/47, 6%) of
them suffered from ICD shocks.
Freedom from the combined study end point (sustained
VT/VF, heart transplant, and death) for the overall population
was 47% (95% CI, 34–65) at 1 year, and 31% (95% CI, 19–49)
at 5 years after the index procedure (Figure 4A). After
multiple procedures, freedom from sustained VT/VF recur-
rence for the overall population was 63% (95% CI, 52–75) at
1 year, and 45% (95% CI, 34–61) at 5 years. Of note, these
rates were achieved with 36% of patients receiving only
endocardial procedures. Figure 4B shows survival rates free
from the combined study end point after the index procedure
stratiﬁed into an endocardial only and combined endo-/
epicardial approach. Although there was a trend for improved
survival rates after the index procedure in patients receiving a
combined endo-/epicardial approach as compared with an
endocardial only approach, this difference was not statistically
signiﬁcant (hazard ratio endo-/epicardial versus endo 0.556
[0.266, 1.162]; P=0.119, Figure 4B). Thirty-six percent (95%
CI, 22–61) of the patients in the endocardial ablation group
were free from the combined end point at 1 year after the
index procedure, whereas the combined endo-/epicardial
ablation group showed an event-free survival of 63% (95% CI,
44–89) at 1 year (Figure 4B). This trend was accentuated
after multiple procedures for the end point of sustained VT/
VF. After multiple procedures, sustained VT/VF free survival
was higher in the combined endo-/epicardial ablation group
at 1 year (75%; 95% CI, 61–93) and at 5 years (54%; 95% CI,
37–77) as compared with endocardial only ablation (53%, 95%
CI, 39–71) at 1 year; and 39% (95% CI, 24–63) at 5 years,
respectively; hazard ratio: endo-/epicardial versus endocar-
dial 0.572 (0.321, 1.020); P=0.058] (Figure 4C).
The number of patients taking AAD at last follow-up was
not statistically different as compared with baseline (n=44/47
[94%] versus n=42/47 [89%]; P=0.72). A considerable
proportion of patients (11/42, 26%) was only on beta-
blockers at last follow-up.
Predictors of Successful Ablation
We analyzed several co-variables to identify possible predic-
tors of the combined study end point after catheter ablation of
VT in patients with ARVC/D. Amongst the parameters age,
sex, body mass index, physical activity (endurance sports),
desmosomal mutation status, ARVC/D task force score,
presence of an ICD, and ablation approach, we did not identify
any signiﬁcant variable.
Discussion
This study reports acute success and long-term outcomes
after catheter ablation of sustained VT in patients with ARVC/
D at our tertiary care center using a sequential ablation
strategy. This sequential strategy ﬁrst targets the endocardial
substrate, and epicardial ablation is performed only in cases
of acute ablation failure or lack of an endocardial substrate.
The main study ﬁndings are as follows: (1) High acute success
rate of 96% (80% complete and 16% partial VT abolition); (2)
After a median follow-up of 50.8 (18.6; 99.2) months after the
index procedure, 17 (17/47, 36%) patients were free from
sustained VT/VF, heart transplant, and death; (3) After
multiple procedures, freedom from sustained VT/VF for the
overall population was 63% at 1 year, and 45% at 5 years; (4)
A non-signiﬁcant trend towards improved outcomes using a
combined endo-/epicardial approach as compared with an
endocardial only approach was observed, with a freedom from
sustained VT/VF of 54% at 5 years in the endo-/epicardial
group; (5) Repeat epicardial access by needle puncture was
impaired by pericardial adhesions in 14% (4/28 patients with
epicardial access) of patients.
Figure 2. Box plot ﬁgure illustrating sustained ventricular
tachycardia/ventricular ﬁbrillation (VT/VF) episodes pre and post
index procedure. N=28, since only patients with implantable
cardioverter-deﬁbrillators (ICD) (before ablation procedure) and
complete interrogation data were analyzed. Median follow-up time
in these patients was 37.2 [2.5; 78.8] months after the index
procedure.
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Figure 3. Endocardial electroanatomical voltage mapping and targeted clinical ventricular tachycardias (VT) in a
patient with deﬁnite arrhythmogenic right ventricular cardiomyopathy/dysplasia (harboring a digenic heterozygous
PKP-2/DSP mutation), who presented with electrical storm and multiple implantable cardioverter-deﬁbrillator
interventions before the index ablation procedure. During endocardial mapping, abnormal substrate was found in the
subtricuspid area and in the right ventricular outﬂow tract. Ablation only via an endocardial approachwas performed,
and has been successful with no more sustained VT/ventricular ﬁbrillation episodes after a follow-up of 2 years. A,
Intracardiac electrograms of termination of VT during catheter ablation in the RVOT region (upper pink point) and (B)
shows corresponding endocardial electroanatomical map.C andD, Displays a perfect pacemap of a second VT in the
subtricuspid region in the same patient (red arrow). RAO indicates right anterior oblique. I, II, III, aVR, aVL, V1-V6
indicates surface 12-lead ECG; Map d/p, bipolar signal on the distal (d) and proximal (p) electrodes of the ablation
catheter; Map uni, unipolar signal on the ablation catheter; RV, signal from the catheter in the right ventricular apex.
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Previous Studies
Our study investigating a sequential approach for catheter
ablation of sustained VT in patients with ARVC/D demon-
strates a high acute success rate of 96%, but a high
recurrence rate of 69% after a single procedure for the
combined study end point (sustained VT/VF, heart transplant,
and death), and a modest recurrence rate of 55% after
multiple procedures for any sustained VT/VF during a follow-
up (F/U) of 5 years. An important factor is the progressive
nature of the disease,25 which may explain the modest long-
term results that have been observed after catheter ablation
of VT in patients with ARVC/D in the current and in previous
studies.26
In line with these ﬁndings, it is well known that patients with
ARVC/D may need multiple ablation procedures.27 However,
previous studies on the outcome of catheter ablation for
sustained VT in ARVC/D report varying results.11,17,27,28
Santangeli et al28 recently demonstrated 71% freedom from
VT after endocardialadjuvant epicardial ablation at 4 years
of F/U. Dalal et al reported a lower VT free survival of 15% at
14 months of F/U in an endocardial ablation study.27 Similar
results were observed after endocardial ablation byMarchlinski
and by Verma et al.29,30 Besides adjuvant epicardial ablation,
another reason for the observed differences could be the use of
3D electroanatomical mapping systems in more recent studies,
since older studies have not systematically used these systems.
Our data are in line with recent studies, who reported
improved outcomes using 3D mapping systems, since we
know that this may facilitate characterization of the patho-
logical substrate and ablation. An important ﬁnding of our
study is that although single procedural success rates using a
sequential approach are low, VT/VF free survival during long-
term F/U can be improved after multiple procedures, even in
patients who never receive epicardial ablation, since more
than one-third of our patient population only received
endocardial ablation. Of note, there was no signiﬁcant
difference in outcome between the only endocardial and the
combined endo-/epicardial approach after the index proce-
dure (P=0.119; Figure 4B), although a trend towards improved
outcomes with adjunct epicardial ablation was depicted.
Similar results were recently published from another German
study group. During the index procedure, patients only
received adjuvant epicardial ablation if the clinical VT was
still inducible after endocardial ablation. The results from
Leipzig showed no difference between endocardial only
(56.5%) and a combined endo-/epicardial approach (59.1%)
in freedom from sustained VT after a F/U of 31 months.18 In
comparison with our study, F/U was shorter, and M€ussigbrodt
et al only reported recurrence-free survival rates after the
index procedure, but did not investigate VT/VF-free survival
after multiple procedures.
Figure 4. A, Kaplan–Meier plot illustrating survival rates free
from the combined study end point (sustained ventricular tachy-
cardia/ventricular ﬁbrillation, heart transplantation, and death)
after the index procedure. The graph shows data for the whole
study cohort (n=47). B, Kaplan–Meier plot illustrating survival rates
free from the combined study end point after the index procedure
stratiﬁed into an endocardial only and combined endo-/epicardial
approach (P=0.119). C, Kaplan–Meier plot illustrating survival
rates free from sustained ventricular arrhythmia recurrence after
multiple procedures. It shows a statistically non-signiﬁcant trend
(P=0.058) towards a better outcome for patients receiving a
combined endo-/epicardial procedure as compared with patients
only receiving endocardial catheter ablation. Endo indicates
endocardial; epi/endo, epi-/endocardial.
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Pathologic Substrate in ARVC/D
In this study, the area of epicardial low voltage was 2 times
larger as compared with the endocardial low voltage area,
which seems to constitute a typical feature of ARVC/D.31
Furthermore, we observed that the pathological process in the
RV of patients with ARVC/D referred for catheter ablation of
VT shows a characteristic “C-shape pattern” extending from
the RVOT free wall to the inferior RV. This pattern was more
frequently visible on epicardial maps. In line with previous
studies, the pathological process of ﬁbro-fatty inﬁltration
seems to start in the subtricuspid region, then extending
towards the RVOT free wall, and the RV apex is involved at
more advanced disease stages.8 Our observations on the
amount and localization of the pathological substrate were
similar for patients with deﬁnite and borderline ARVC/D,
suggesting that they had the “same” disease.
The combination of the presence of a larger RV
epicardial substrate as compared with the RV endocardium,
the typical “C-shape” low voltage area in the RV, and the
disease onset in the subtricuspid region with conﬂuent
disease spreading towards the RVOT and RV inferior wall
seem to be speciﬁc markers of ARVC/D. These important
observations seem to contrast to phenocopies of ARVC/D
such as RV myocardial infarction, myocarditis or cardiac
sarcoid, with the latter 2 entities frequently showing a
rather patchy scar formation.32
Endocardial or Epicardial Ablation as First Line
Therapy
Recent evidence indicates that combined endo-/epicardial
ablation yields superior outcomes as compared with an
endocardial only ablation strategy.10–13 Yet, given the risks of
an epicardial access, it is still debated whether a pure
endocardial or combined endo-/epicardial approach should
be chosen as ﬁrst line therapy. Garcia et al proposed an
epicardial approach as ﬁrst line therapy in 2009. Interestingly,
with growing experience on catheter ablation of VT and
improved tools, the same group proposed an endocardial
approach as ﬁrst line therapy and adjuvant epicardial ablation
only if needed.28 Initially the authors hypothesized in their
ﬁrst manuscript a thicker endocardial layer in ARVC/D
patients, which may only be targeted sufﬁciently from the
epicardium. The authors performed measurements of over-
lapping endocardial and epicardial surfaces in 3D EAM to
determine the wall thickness of the basal and free wall of the
RV. However, this method lacks accuracy, and the gold
standard for measuring RV wall thickness in vivo is cardiac
magnetic resonance imaging (MRI), or autopsy studies ex vivo.
RV thickness is usually ≤3 mm, and even thinner in diseased
RV areas of patients with ARVC/D.33 Modern open-irrigated
ablation catheters using RF energy can achieve ablation
lesions with a depth of up to 7 to 8 mm with standard power
settings and a stable catheter position,34 which should
theoretically enable a transmural lesion from the endocardial
surface. Accordingly, a recent study evaluated the effect of
endocardial elimination of local abnormal ventricular activi-
ties. The authors stated that local abnormal ventricular
activities elimination by potent endocardial ablation could
result in epicardial local abnormal ventricular activities
elimination in at least 73% of patients with ARVC/D.21 In
line with these considerations, our data showed no signiﬁcant
difference between the endocardial and epicardial approach,
and a considerable number of patients receiving only
endocardial ablation did not suffer from sustained VT/VF
during F/U, or in case of a sustained arrhythmia, were shifted
from ICD shocks to painless ATP. ATP was considered as an
equivalent end point to ICD shocks, which is in line with
previous studies, but ATP as compared with ICD shocks
implies a signiﬁcant improvement from a clinical point of view
that is often neglected in ICD studies. This was shown by a
recent study, where patients who only received ATP instead of
high voltage shocks had a reduced mortality and hospitaliza-
tion rate.35
Complications of Epicardial Ablation
Improved long-term outcome should overweigh potential risks
of complications. Sacher et al reported a complication rate of
up to 8% for epicardial VT ablation,15 and studies from high-
volume centers have even reported fatalities associated with
an epicardial approach.15–17,31
In the current study, the 1 severe complication, a
pericardial tamponade, was attributed to the epicardial
access. Moreover, an early epicardial procedure may impair
access to the pericardial space for future procedures. In the
current study, this was the case in 14% of patients (4/28
patients with pericardial access) who received epicardial
mapping precluding any further percutaneous epicardial
ablation. In some patients this could even result in an
avoidable surgical procedure with surgical adhesiolysis, which
may increase the risk of severe complications. Furthermore,
prolonged procedure times and increased radiation using an
epicardial approach as compared with an endocardial
approach, as shown in the current study, should also be
considered. Given the risks of an epicardial approach, longer
procedure times and higher ﬂuoroscopy doses, and the
aforementioned considerations on RV wall thickness and
lesion depth, an endocardial approach as ﬁrst line therapy—
and only performing additional epicardial ablation if no
endocardial substrate can be identiﬁed or if clinical VT is
still inducible after extensive endocardial ablation—seems to
be reasonable. Such a sequential approach may be consid-
ered by less experienced centers. Yet, our data underline the
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need of extensive endocardial ablation with good contact and
stable catheter position before considering an epicardial
approach. This may be particularly relevant for young patients
with ARVC/D, who may need several ablation procedures, and
an epicardial ablation that is performed too early may cause
signiﬁcant pericardial adhesions precluding further percuta-
neous epicardial access.
Predictors of VT/VF Recurrence
We analyzed several potential clinical predictors of VT/VF
recurrence. However, no signiﬁcant association between
these parameters and outcome was demonstrated, which is
in line with previous reports.36 In those patients in whom
genetic testing was performed, no statistical difference in
outcome after catheter ablation was found for those with and
without desmosomal mutations. The role of physical activity
and outcome in ARVC/D is debated. Endurance athletes have
been shown to be associated with adverse outcome, also after
catheter ablation.13 In our population, there was a high
number of former endurance athletes. Yet, no patient was an
active endurance or competitive athlete at last F/U, which
might have inﬂuenced our results on long term F/U after VT
ablation. AAD may also inﬂuence VT recurrence and outcome.
We did not observe a signiﬁcant reduction in the rate of
patients taking betablockers and AAD at last F/U as
compared with baseline, which implies that ARVC/D is a
progressive disease and catheter ablation alone may not be
sufﬁcient to control arrhythmias.
Limitations
Our study has some limitations. This was not a prospective
randomized trial, data on EAM and ICD interrogations were not
complete in all patients, and therefore our results are rather
hypothesis-generating. It would be of great interest to analyze
differences in outcome between the sequential approach and
combined endo--epicardial ablation as ﬁrst line therapy in a
randomized fashion, but in rare diseases such as ARVC/D this
will need a global collaborative approach. Furthermore, patients
were treated in a high-volume center, conferring a signiﬁcant
risk of selection bias, and our results may not be applicable to
centers with a lower ablation volume. Accordingly, the majority
of patients presented with an endocardial substrate reﬂecting
that these patients had rather advanced stages of the disease,
limiting the generalizability of our data. We included some
patients with borderline ARVC/D who did not fulﬁl the deﬁnite
2010 ARVC/D task force criteria. From a clinical perspective,
these patients showed the full ARVC/D phenotype, however,
since they were referred to us from other hospitals for VT
ablation, we did not assign all 2010 diagnostic criteria.
Furthermore, we would like to indicate that even if these
patients do not fulﬁll deﬁnite criteria, they form an important
part of our daily clinical work and it is important to assess the
efﬁcacy and safety of VT ablation also in these patients with a
borderline diagnosis.
Despite being considerable for such a rare disease and
complex intervention, patient numbers are still too low to
account for various confounders and to analyze subgroups.
Thus, our analysis on clinical predictors and VT/VF recurrence
may be underpowered.
Conclusions
Catheter ablation is a generally safe and effective strategy to
reduce sustained ventricular arrhythmia burden in patients
with ARVC/D. Although the pathologic process in ARVC/D
typically begins in the subepicardium, endocardial ablation
seems to be effective in a considerable number of patients,
potentially obviating the need for an epicardial approach in
some of these patients.
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